151 results on '"Canepa, L"'
Search Results
2. Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma
3. Long-Term Effects of Hypoxia-Reoxygenation on Thioredoxins in Rat Central Nervous System
4. Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse
5. Melphalan, Prednisone and Lenalidomide: Kinetics of Hematologic Toxicity and Time to Event Results: B094
6. RMPT in Relapsed/Refractory Multiple Myeloma: Results of a Multicenter Phase II Clinical Trial: A092
7. Long-Term Effects of Hypoxia-Reoxygenation on Thioredoxins in Rat Central Nervous System
8. First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease
9. Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide
10. ORAL MELPHALAN, PREDNISONE AND LENALIDOMIDE TREATMENT FOR NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS
11. ORAL MELPHALAN, PREDNISONE AND LENALIDOMIDE FOR ELDERLY NEWLY DIAGNOSED MYELOMA PATIENTS
12. Oral lenalidomide plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma
13. ORAL REVLIMID PLUS MELPHALAN AND PREDNISONE (R-MP) FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: A PHASE I-II STUDY
14. Combination of liposomal Daunorubicin, Fludarabine, and Cytarabine (FLAD) in patients with poor- risk acute leukemia
15. Studio sperimentale dell'accoppiamento rollio-sloshing per un peschereccio con un compartimento allagato in mare regolare al traverso
16. Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse
17. First line therapy with Fludarabine combinations in 42 patients with either post-myelodysplastic syndrome or therapy related acute myeloid leukaemia
18. Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment?
19. Thalidomide in agnogenic and secondary myelofibrosis
20. Detection of minimal residual disease in B-lymphoproliferative disorders: a three step SSCP-PCR method
21. Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens
22. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia
23. Fludarabine in untreated and previously treated B-CLL patients: a report on efficacy and toxicity
24. Thalidomide-induced cardiotoxicity in multiple myeloma patients: An underestimated but clinically relevant issue.
25. An unusual reaction to alpha interferon in a case of non Hodgkin's lymphoma
26. First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease
27. A092 RMPT in Relapsed/Refractory Multiple Myeloma: Results of a Multicenter Phase II Clinical Trial
28. B094 Melphalan, Prednisone and Lenalidomide: Kinetics of Hematologic Toxicity and Time to Event Results
29. Bound and unbound pyridine dinucleotides in normal and glucose-6-phosphate dehydrogenase-deficient erythrocytes
30. Oral lenalidomide plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma
31. 72 Recruitment and identification of “normal” hematopoietic cells in MDS
32. Mobilizatiod/Transplantation of Peripheral Blood Progenitor Cells for Aggressive Non-Hodgkin's Lymphoma with Marrow Involvement
33. Anaplastic Large Cell Lymphoma: A Clinicopathologic Study of 53 Patients
34. Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results.
35. Urinary Granulopoietic Activity in Chronic Myelogenous Leukemia: Follow-Up and Correlation with Various Phases of the Disease.
36. The Action of Acth, Cortisone and Prednisone on the Connective Tissue of Normal and Sclerodermic Human Skin**From the Instituto de Anatomía General y Embriologia, Facultad de Ciencias Medicas, Buenos Aires, Argentina
37. PO023 High dose of r-EPO (40,000 IU) once a week is highly effective in a selected cohort of MDS patients with basal EPO level
38. Catalase and glutathione peroxidase are equally active in detoxification of hydrogen peroxide in human erythrocytes
39. Clonal origin of cells restricted to monocytic differentiation in acute nonlymphocytic leukemia
40. Primary thrombocythemia: clonal origin of platelets, erythrocytes, and granulocytes in a GdB/GdMediterranean subject
41. Fluorescence in situ hybridization provides evidence for two-step rearrangement in a masked Ph chromosome formation
42. The Action of Acth, Cortisone and Prednisone on the Connective Tissue of Normal and Sclerodermic Human Skin1
43. Tecnologias da Comunicação, Horror e Ficção Científica: o caso de três filmes brasileiros
44. Epidemiologia dell'influenza in allevamenti di suini dell'Italia Settentrionale nell'inverno 1980/81
45. MARKED KARYOTYPE ABNORMALITIES IN 2 CASES OF ACUTE MYELOGENOUS LEUKEMIA
46. Clonal analysis of hematologic malignancies using Mediterranean G6PD mosaicism
47. Myelofibrosis: Report of five cases treated with thalidomide
48. ERWINIA CHRYSANTEMI-DERIVED L-ASPARAGINASE STRONGLY ENHANCES ANTI-MM DRUGS ACTIVITY BY DERE-GULATING METABOLIC CELL PROGRAM
49. MITOXANTRONE, ETOPOSIDE, ARA-C AND LOW DOSE GEMTUZUMAB OZOGAMICIN (MY-MEC) AS SALVAGE THERAPY FOR RELAPSED-REFRACTORY AML PATIENTS
50. GM-CSF, ARA-C, VP-16 and idarubicin (GM-IVA), a short, and effective induction treatment for de novo AML, suitable for the elderly
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.